This Wiki is currently under construction
For the complete documentation index, see llms.txt. This page is also available as Markdown.

mechanisms of malabsorption

Section: Complete Biochemistry → Transporters & Absorption Reading level: Technical, with a plain-language summary Last reviewed: October 2026

Summary

Absorbing thiamine requires several steps to work: thiamine must be released from food, reach a healthy stretch of small intestine, be carried into intestinal cells by transporters, and then exit into the blood. Malabsorption occurs when disease or treatment disrupts one or more of these steps.

The best-documented causes are chronic alcohol use, which suppresses the intestinal thiamine transporters, and bariatric surgery, which combines reduced intake, intestinal bypass and vomiting. Other causes include loss of absorptive surface, rapid transit, drugs that block the transporters, bacterial overgrowth and coexisting nutrient deficiencies. In practice, malabsorption usually combines with poor intake or increased losses rather than acting alone.

The steps of absorption and how each can fail

Step
Normal process
Failure modes

1. Release from food

Phosphatases convert dietary TPP and TMP to free thiamine

Severe mucosal damage reducing brush-border enzyme activity; dietary thiaminases destroying thiamine (see GI Factors)

2. Contact with absorptive surface

Free thiamine reaches duodenum and jejunum

Surgical bypass; vomiting; rapid transit; reduced surface area

3. Apical uptake

THTR-2 and THTR-1 carry thiamine into enterocytes (saturable)

Reduced transporter expression (alcohol, inflammation); drug inhibition; genetic defects

4. Intracellular handling

Thiamine crosses the enterocyte

Experimental evidence that alcohol impairs this stage

5. Basolateral exit

THTR-1 moves thiamine into blood

Suppression by alcohol (historical evidence)

6. Colonic uptake of microbial thiamine

Colonocytes absorb bacterial thiamine and TPP

Colectomy; altered microbiota; contribution uncertain

Mechanisms in detail

Reduced transporter function

Cause
Mechanism

Chronic alcohol use

Reduced expression of THTR-1 and THTR-2 in intestine (and kidney); older studies also showed impaired active transport and basolateral exit

Drugs inhibiting THTR-2

Fedratinib, metformin and trimethoprim inhibit THTR-2 in vitro; intestinal THTR-2 is a plausible site of interaction

Genetic transporter defects

SLC19A2 mutations (TRMA) reduce THTR-1 function; absorption continues via THTR-2 and passive diffusion

Inflammation

Experimental studies suggest inflammatory signals can reduce transporter expression

Loss of absorptive surface or contact time

Cause
Mechanism

Short bowel syndrome

Reduced length of absorptive intestine

Coeliac disease (untreated)

Villous atrophy reduces surface area

Crohn's disease affecting the small intestine

Inflammation and resection

Chronic diarrhoea, rapid transit

Reduced contact time

Radiation enteritis, chemotherapy mucositis

Mucosal injury

Bariatric (weight-loss) surgery

Thiamine deficiency, including Wernicke encephalopathy, is well documented after bariatric surgery. Most cases occur in the first months after surgery and are associated with persistent vomiting. Contributing mechanisms include:

  • reduced food intake;

  • bypass of the duodenum and proximal jejunum in Roux-en-Y gastric bypass and biliopancreatic diversion, removing the main absorption site from the food stream;

  • pre-absorptive losses from vomiting;

  • small intestinal bacterial overgrowth in the bypassed or blind limb.

A study of patients after Roux-en-Y gastric bypass found that thiamine deficiency was associated with bacterial overgrowth and improved when the overgrowth was treated with antibiotics.

Pre-absorptive losses

Vomiting (hyperemesis gravidarum, eating disorders, gastric outlet obstruction, post-surgical complications) removes thiamine before it reaches absorptive sites. Because thiamine stores are small, prolonged vomiting can cause deficiency within weeks.

Small intestinal bacterial overgrowth (SIBO)

Bacteria in the small intestine can compete for thiamine. Some species produce thiaminases that destroy it. Evidence linking SIBO to clinical thiamine deficiency comes mainly from bariatric surgery studies and case reports. SIBO is a heterogeneous condition, and its effect on thiamine in other settings is not well characterized.

Coexisting nutritional deficiencies

Deficiency
Effect on thiamine absorption

Folate

Folate-deficient rats showed impaired thiamine absorption, possibly through effects on intestinal cell turnover

Protein-energy malnutrition

Mucosal atrophy and reduced enzyme and transporter expression

Magnesium

Does not impair absorption, but impairs conversion of absorbed thiamine to TPP

Why alcohol is so damaging

Alcohol affects thiamine absorption in several ways:

  • Acute exposure inhibits active thiamine transport.

  • Chronic exposure lowers THTR-1 and THTR-2 messenger RNA and protein levels in intestinal cells.

  • Classic studies in malnourished people with alcohol use disorder showed reduced absorption of radiolabelled thiamine, which improved after abstinence and nutritional repletion.

  • Older work also implicated impaired basolateral exit from enterocytes.

These absorptive effects combine with poor intake, reduced hepatic storage, impaired phosphorylation and increased urinary loss (see Causes of Deficiency).

Assessing malabsorption

There is no routine clinical test of thiamine absorption. In research, absorption has been studied with radiolabelled thiamine and by comparing blood or urine levels after oral and intravenous doses. In clinical practice, malabsorption is usually inferred from the underlying condition, low thiamine status despite apparently adequate intake, or response to non-oral routes.

Routes around malabsorption (informational)

The following strategies are described in the literature. Choice of approach in any individual is a clinical decision.

Strategy
Rationale

Parenteral thiamine (intravenous or intramuscular)

Bypasses the gut entirely

High oral doses

At high luminal concentrations, passive diffusion supplements carrier-mediated uptake; absorption continues to rise with dose up to at least 1,500 mg in healthy people

Lipid-soluble derivatives

Absorbed largely independently of THTR-1/2

Treating the underlying cause

For example, abstinence from alcohol, treatment of SIBO, gluten-free diet in coeliac disease

Open questions

  • How much do IBD, coeliac disease and other enteropathies reduce thiamine absorption in people, independent of intake?

  • Does SIBO outside the bariatric setting meaningfully affect thiamine status?

  • Which absorption strategy works best in people with established malabsorption? Comparative studies are lacking.

  • Thiamine Transporters

  • GI Factors Affecting Thiamine Uptake

  • Thiamine Derivatives

  • Causes of Deficiency

References

  1. Said HM. Intestinal absorption of water-soluble vitamins in health and disease. Biochemical Journal. 2011;437(3):357–372.

  2. Hoyumpa AM Jr. Mechanisms of thiamin deficiency in chronic alcoholism. American Journal of Clinical Nutrition. 1980;33(12):2750–2761.

  3. Thomson AD, Baker H, Leevy CM. Patterns of ³⁵S-thiamine hydrochloride absorption in the malnourished alcoholic patient. Journal of Laboratory and Clinical Medicine. 1970;76(1):34–45.

  4. Subramanya SB, Subramanian VS, Said HM. Chronic alcohol consumption and intestinal thiamin absorption: effects on physiological and molecular parameters of the uptake process. American Journal of Physiology: Gastrointestinal and Liver Physiology. 2010;299(1):G23–G31.

  5. Aasheim ET. Wernicke encephalopathy after bariatric surgery: a systematic review. Annals of Surgery. 2008;248(5):714–720.

  6. Lakhani SV, et al. Small intestinal bacterial overgrowth and thiamine deficiency after Roux-en-Y gastric bypass surgery in obese patients. Nutrition Research. 2008;28(5):293–298.

  7. Howard L, Wagner C, Schenker S. Malabsorption of thiamin in folate-deficient rats. Journal of Nutrition. 1977;107(5):775–782.

  8. Zhang Q, et al. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy. Drug Metabolism and Disposition. 2014;42(10):1656–1662.

  9. Liang X, et al. Metformin is a substrate and inhibitor of the human thiamine transporter, THTR-2 (SLC19A3). Molecular Pharmaceutics. 2015;12(12):4301–4310.

  10. Smithline HA, Donnino M, Greenblatt DJ. Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects. BMC Clinical Pharmacology. 2012;12:4.

  11. Galvin R, et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. European Journal of Neurology. 2010;17(12):1408–1418.

Editorial note: This page describes mechanisms and published evidence. It is not medical advice and does not recommend doses. Suggest corrections or new sources via the feedback link.

Was this helpful?